Ajanta Pharma Announces the Launch of Aripiprazole Tablets

Bridgewater : Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, announces the launch of Aripiprazole Tablets (2.5mg, 5mg, 10mg, 15mg, 20mg, 30mg), a bioequivalent generic version of Abilify®, into the US market.

Aripiprazole Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 29 Abbreviated New Drug Applications (ANDAs) of which it has 16 final ANDA approvals; 2 tentative approvals; and 11 ANDAs under review with the United States Food & Drug Administration.